Clinical Trials · NCT06045260
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Enrollment
- 100
- Start date
- Sep 2023
- Locations
- 2 sites, Italy
- Primary endpoint
- Efficacy as Disease control rate (DCR)